Monday, September 22, 2014

TKM-EBOLA Making RNAi History

Today, Tekmira disclosed that an acceptable regulatory pathway has been found with US and Canadian regulators to use its RNAi Therapeutic against Ebola infection, TKM-EBOLA, in the current outbreak.  In fact, the company added that 'TKM-Ebola, has been administered to patients on an emergency basis and the repeat infusions have been well-tolerated'.

While not going into specifics, it is more or less a confirmation that Dr Sacra who was said to have received multiple courses of a treatment was indeed treated with TKM-EBOLA (he seems to have pulled through).  Further substantiating that suspicion was a comment by a relative that subsequent administrations of the experimental drug were better tolerated:

'He also tolerated the research drug well – better than he had the previous doses he was given.”'

This is consistent with infusion reactions of many intravenously administered drugs being a particular problem during the first administration only.

Then there was another report that a number of suspected, early cases had been evacuated from Western Africa to the US with the intention of giving them experimental treatments.  This, in fact, would be the ideal setting for using TKM-EBOLA, or for that matter most other experimental treatments against Ebola.  It should be remembered that while in the preclinical monkey studies, the efficacy of TKM-EBOLA started to wane if treatment was delayed for more than 3 days following infection of the animal, this experimental setting is more akin to a needle stick accident in the lab given the large amount of virus involved in the innoculum.

By contrast, in the current outbreak in Western Africa, not every contact obviously leads to a successful transmission of the virus, a reflection of the fact that the starting viral population will be much less compared to the experimental setting.  This means that it would take the virus more than 3 days to overwhelm the capacity of TKM-EBOLA and the immune system to stall the infection in its tracks.  Hopefully, Tekmira is conducting analogous innoculum-window-of-opportunity studies in monkeys to get a better sense of how much treatment can be delayed when infectious doses are quite low.

With this in mind, I am more or less convinced that RNAi Therapeutics is saving patient lives for the first time.  I personally would risk an anaphylactic shock in a closely supervised clinical setting any day over the prospect of not getting specific treatment when infected with Ebola. #RNAiHistory


Anonymous said...

Sorry to hear you are all out of this stock. I told you stop trading this superstar. Buy and hold.

Anonymous said...

Dirk, you have conveniently forgotten how many lives Gradalis has saved. Oh sorry, that's RNAi therapuetics without a capital T.

I think it's great what TKMR are doing but you should not let your pocket get in the way of your facts.

Anonymous said...

Have you seen the @bhgreeley message on Ebola? Checkout Bloomberg Businessweek and video.

Brendan Greeley and Caroline Chen uncover that the Ebola drug ZMapp's development was delayed by a Pentagon agency, or as their headline deftly puts it, "How the U.S. Screwed Up in the Fight Against Ebola" (681 shares). " A little-known Pentagon agency had a promising treatment for Ebola — IN 2010 — and failed to act," BW editor Janet Paskin laments.

Are their facts correct or is it possible that USA Gov’t chose Tekmira over ZMapp? The authors seem to be silent to $40MM received by TKMR in research grants from US Dept of Defense.

With UN focus this week on Ebola (following global warming, and terrorism), TKMR public stock could explode.

UN is forming $1 BB effort to fight Ebola.

Anonymous said...


What do you think is the next catalyst for RGDO? Is there a reason other than their cash on hand to start a small position?

Anonymous said...

... on Tekmira homepage I can not find the Tekmira press release from 22.Sept anymore, where they stated that "TKM-Ebola has been administered to a number of patients". Can someone provide a link to the official press release please?

Anonymous said...

RGDO....look out's that trade working guys....dead cat no bounce yikes

Retta Matson said...

Interesting article, trying to find some more articles. Kindly Provide me more sources so I can explore more about it.

By Dirk Haussecker. All rights reserved.

Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.